Tracking migraine outcomes over time by age and monoclonal antibody type: a retrospective, single-center, real-world study.

This study looked at how different CGRP monoclonal antibodies (mAbs) help adults with migraines. Researchers tracked 453 patients aged under 50 and over 50. They used four types of mAbs: erenumab, galcanezumab, fremanezumab, and eptinezumab. The goal was to see if age or treatment type affected migraine outcomes. Patients reported their monthly migraine days, medication use, pain levels, disability, quality of life, and mood over a year. The findings showed varying responses based on age and the specific treatment used. Overall, the study aimed to understand how these treatments work over time. This information can help doctors choose the best migraine treatment for different patients. By analyzing long-term data, researchers hope to improve migraine management and patient care. Clinical relevance: This study highlights the importance of tailoring migraine treatments based on age and specific monoclonal antibody type for better patient outcomes.